MicroRNA-522 reverses drug resistance of doxorubicin-induced HT29 colon cancer cell by targeting ABCB5

Yang,Ge; Jiang,Ou; Ling,Daiqiong; Jiang,Xiaoyue; Yuan,Pingzong; Zeng,Guang; Zhu,Jing; Tian,Jie; Weng,Yaguang; Wu,Daoquan

doi:10.3892/mmr.2015.3890

MicroRNA-522 reverses drug resistance of doxorubicin-induced HT29 colon cancer cell by targeting ABCB5

Authors:
- Ge Yang
- Ou Jiang
- Daiqiong Ling
- Xiaoyue Jiang
- Pingzong Yuan
- Guang Zeng
- Jing Zhu
- Jie Tian
- Yaguang Weng
- Daoquan Wu
View Affiliations

Affiliations: Clinical Laboratory, Affiliated Second People's Hospital of Luzhou Medical College, Neijiang, Sichuan 641000, P.R. China, Key Laboratory of Diagnostic Medicine Designated by the Chinese Ministry of Education and School of Diagnostic Medicine, Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: June 4, 2015 https://doi.org/10.3892/mmr.2015.3890
Pages: 3930-3936

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs, which are important in the development of multidrug resistance in cancer by regulating gene expression at the post‑transcriptional level. The present study investigated the functional effects of miR‑522 in chemoresistant colon cancer cells. The results demonstrated that miR‑522 was significantly downregulated in doxorubicin (DOX) resistant colon cell line, HT29/DOX, compared with the parental HT29 colon cancer cell line. Overexpression of miR‑522 in the HT29/DOX cells partially restored DOX sensitivity. miRNA target prediction algorithms suggested that ABCB5 was a target gene for miR‑522. A fluorescent reporter assay confirmed that miR‑522 was able to specifically bind to the predicted site of the ABCB5 mRNA 3'‑untranslated region. When miR‑522 was overexpressed in the HT29/DOX cells, the protein expression levels of ABCB5 were downregulated. Furthermore, knockdown of ABCB5 significantly increased the growth inhibition rate of the HT29/DOX cells, compared with the control group. These results suggested that miR‑522 may affect the sensitivity of colon cancer cell lines to DOX treatment by targeting ABCB5.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
2	Sung JJ, Lau JY, Goh KL and Leung WK; Asia Pacific Working Group On Colorectal Cancer: Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol. 6:871–876. 2005. View Article : Google Scholar : PubMed/NCBI
3	Climent J, Dimitrow P, Fridlyand J, et al: Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. Cancer Res. 67:818–826. 2007. View Article : Google Scholar : PubMed/NCBI
4	Bartel DP: MicroRNAs: genomics, biogenesis, mechanism and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
5	Lee Y, Kim M, Han J, et al: MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 23:4051–4060. 2004. View Article : Google Scholar : PubMed/NCBI
6	Lee Y, Jeon K, Lee JT, Kim S and Kim VN: MicroRNA maturation: stepwise processing and subcellular localization. EMBO J. 21:4663–4670. 2002. View Article : Google Scholar : PubMed/NCBI
7	Han J, Lee Y, Yeom KH, Kim YK, Jin H and Kim VN: The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 18:3016–3027. 2004. View Article : Google Scholar : PubMed/NCBI
8	Lee Y, Ahn C, Han J, et al: The nuclear RNase III Drosha initiates microRNA processing. Nature. 425:415–419. 2003. View Article : Google Scholar : PubMed/NCBI
9	Lund E, Güttinger S, Calado A, Dahlberg JE and Kutay U: Nuclear export of microRNA precursors. Science. 303:95–98. 2004. View Article : Google Scholar
10	Hutvagner G, McLachlan J, Pasquinelli AE, Bálint E, Tuschl T and Zamore PD: A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science. 293:834–838. 2001. View Article : Google Scholar : PubMed/NCBI
11	Peters L and Meister G: Argonaute proteins: mediators of RNA silencing. Mol Cell. 26:611–623. 2007. View Article : Google Scholar : PubMed/NCBI
12	Parker JS and Barford D: Argonaute: A scaffold for the function of short regulatory RNAs. Trends Biochem Sci. 31:622–630. 2006. View Article : Google Scholar : PubMed/NCBI
13	Pillai RS, Bhattacharyya SN and Filipowicz W: Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol. 17:118–126. 2007. View Article : Google Scholar : PubMed/NCBI
14	Felli N, Fontana L, Pelosi E, et al: MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci USA. 102:18081–18086. 2005. View Article : Google Scholar : PubMed/NCBI
15	Li J, Huang H, Sun L, et al: MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res. 15:3998–4008. 2009. View Article : Google Scholar : PubMed/NCBI
16	Wang S, Aurora AB, Johnson BA, et al: The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 15:261–271. 2008. View Article : Google Scholar : PubMed/NCBI
17	Xu N, Papagiannakopoulos T, Pan G, Thomson JA and Kosik KS: MicroRNA-145 regulates OCT4, SOX2 and KLF4 and represses pluripotency in human embryonic stem cells. Cell. 137:647–658. 2009. View Article : Google Scholar : PubMed/NCBI
18	Ma L, Young J, Prabhala H, et al: miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 12:247–256. 2010.PubMed/NCBI
19	Huh JH, Kim TH, Kim K, et al: Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer. Br J Cancer. 109:452–461. 2013. View Article : Google Scholar : PubMed/NCBI
20	Fang Y, Shen H, Li H, et al: miR-106a confers cisplatin resistance by regulating PTEN/Akt pathway in gastric cancer cells. Acta Biochim Biophys Sin (Shanghai). 45:963–972. 2013. View Article : Google Scholar
21	Xia L, Zhang D, Du R, et al: miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer. 123:372–379. 2008. View Article : Google Scholar : PubMed/NCBI
22	Fan D, Zhang X, Chen X, et al: Bird's-eye view on gastric cancer research of the past 25years. J Gastroenterol Hepatol. 20:360–365. 2005. View Article : Google Scholar : PubMed/NCBI
23	Zhu H, Wu H, Liu X, et al: Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 76:582–588. 2008. View Article : Google Scholar : PubMed/NCBI
24	Meng F, Henson R, Lang M, et al: Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 130:2113–2129. 2006. View Article : Google Scholar : PubMed/NCBI
25	Colombo V, Lupi M, Falcetta F, Forestieri D, D'Incalci M and Ubezio P: Chemotherapeutic activity of silymarin combined with doxorubicin or paclitaxel in sensitive and multidrug-resistant colon cancer cells. Cancer Chemother Pharmacol. 67:369–379. 2011. View Article : Google Scholar
26	Weinlander G, Kornek G, Raderer M, Hejna M, Tetzner C and Scheithauer W: Treatment of advanced colorectal cancer with doxorubicin combined with two potential multidrug-resistance-reversing agents: high-dose oral tamoxifen and dexverapamil. J Cancer Res Clin Oncol. 123:452–455. 1997. View Article : Google Scholar : PubMed/NCBI
27	Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2:48–58. 2002. View Article : Google Scholar : PubMed/NCBI
28	Simon SM and Schindler M: Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA. 91:3497–3504. 1994. View Article : Google Scholar : PubMed/NCBI
29	Kopnin BP: Targets of oncogenes and tumor suppressors: key for understanding basic mechanisms of carcinogenesis. Biochemistry (Mosc). 65:2–27. 2000.
30	Frank NY, Margaryan A, Huang Y, et al: ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 65:4320–4333. 2005. View Article : Google Scholar : PubMed/NCBI
31	Chen KG, Valencia JC, Gillet JP, Hearing VJ and Gottesman MM: Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. Pigment Cell Melanoma Res. 22:740–749. 2009. View Article : Google Scholar : PubMed/NCBI
32	Chen KG, Szakács G, Annereau JP, et al: Principal expression of two mRNA isoforms (ABCB 5alpha and ABCB 5beta) of the ATP-binding cassette transporter gene ABCB 5 in melanoma cells and melanocytes. Pigment Cell Res. 18:102–112. 2005. View Article : Google Scholar : PubMed/NCBI
33	Wilson BJ, Schatton T, Zhan Q, et al: ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. Cancer Res. 71:5307–5316. 2011. View Article : Google Scholar : PubMed/NCBI
34	Theile D, Ketabi-Kiyanvash N, Herold-Mende C, et al: Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head Neck. 33:959–968. 2011. View Article : Google Scholar